CA2491129A1 - Central airway administration for systemic delivery of therapeutics - Google Patents

Central airway administration for systemic delivery of therapeutics Download PDF

Info

Publication number
CA2491129A1
CA2491129A1 CA002491129A CA2491129A CA2491129A1 CA 2491129 A1 CA2491129 A1 CA 2491129A1 CA 002491129 A CA002491129 A CA 002491129A CA 2491129 A CA2491129 A CA 2491129A CA 2491129 A1 CA2491129 A1 CA 2491129A1
Authority
CA
Canada
Prior art keywords
antibody
aerosol
subject
therapeutic agent
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491129A
Other languages
English (en)
French (fr)
Inventor
Richard S. Blumberg
Wayne I. Lencer
Neil E. Simister
Alan J. Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Childrens Medical Center Corp
Brandeis University
Bioverativ Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/en
Application filed by Individual filed Critical Individual
Publication of CA2491129A1 publication Critical patent/CA2491129A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002491129A 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics Abandoned CA2491129A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2002/021335 WO2003077834A2 (en) 2002-03-15 2002-07-03 Central airway administration for systemic delivery of therapeutics
USPCT/US02/21335 2002-07-03
PCT/US2003/014428 WO2004004798A2 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics

Publications (1)

Publication Number Publication Date
CA2491129A1 true CA2491129A1 (en) 2004-01-15

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491129A Abandoned CA2491129A1 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics

Country Status (5)

Country Link
EP (1) EP1539246A4 (ja)
JP (1) JP2006513139A (ja)
AU (1) AU2003232081B2 (ja)
CA (1) CA2491129A1 (ja)
WO (1) WO2004004798A2 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1711610A2 (en) * 2004-01-28 2006-10-18 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
WO2009012600A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins
EP2203180B1 (en) * 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
CA3086659A1 (en) 2007-12-26 2009-07-09 Xencor, Inc. Fc variants with altered binding to fcrn
ES2742419T3 (es) 2008-09-17 2020-02-14 Xencor Inc Nuevas composiciones y métodos para tratar trastornos mediados por IgE
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
IN2014DN11157A (ja) 2012-07-13 2015-10-02 Roche Glycart Ag
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11471617B2 (en) 2014-04-03 2022-10-18 Csl Behring Ag Nebultzation of immunoglobulin
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
AU2016355563A1 (en) * 2015-11-16 2018-06-21 The Trustees Of The University Of Pennsylvania Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
ES2194973T3 (es) * 1995-01-17 2003-12-01 Brigham & Womens Hospital Transporte de inmunogenes transepitelial especifico del receptor.
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU2002219944B2 (en) * 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
MXPA02009485A (es) * 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
WO2003077834A2 (en) * 2002-03-15 2003-09-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Also Published As

Publication number Publication date
EP1539246A4 (en) 2007-05-16
AU2003232081B2 (en) 2009-02-05
WO2004004798A3 (en) 2004-10-14
JP2006513139A (ja) 2006-04-20
WO2004004798A2 (en) 2004-01-15
EP1539246A2 (en) 2005-06-15
AU2003232081A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
AU2003232081B2 (en) Central airway administration for systemic delivery of therapeutics
US20060140907A1 (en) Central airway administration for systemic delivery of therapeutics
US20040063912A1 (en) Central airway administration for systemic delivery of therapeutics
US7060274B2 (en) Receptor specific transepithelial transport of therapeutics
CA2297101C (en) Receptor specific transepithelial transport of therapeutics
US20090191217A1 (en) Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
KR20160062760A (ko) 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
CA2631981A1 (en) Methods and compositions for needleless delivery of binding partners
EP1589943A2 (en) Methods of treating lung diseases
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
WO2022191158A1 (ja) 抗体－リソソーム酵素融合蛋白質の製造方法
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
WO2016079276A1 (en) Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
TW202405018A (zh) Ｃｄ７３抗體雞尾酒療法
TW201922280A (zh) 用於異位性皮膚炎之抗-il-33 療法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead